Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025)
Nu-Med Plus' (NUMD) quarterly Net Income towards Common Stockholders came in at -$12618.0 in Q4 2025, down 19.55% year-on-year from -$15683.3 in Q4 2024, and down 5.45% quarter-over-quarter from -$11966.0 in Q3 2025.
Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025) Analysis & Trends
Nu-Med Plus has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting -$12618.0 for Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$12618.0, down 19.55% year-over-year; the trailing twelve-month figure through Dec 2025 was -$56182.0 (up 17.8% YoY), and the FY2025 annual result was -$56182.0, up 17.8% from the prior year.
- Net Income towards Common Stockholders came in at -$12618.0 for Q4 2025 at Nu-Med Plus, down from -$11966.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $42606.0 in Q4 2022 to a low of -$356748.0 in Q1 2021.
- The 5-year median for Net Income towards Common Stockholders is -$23073.0 (2023), against an average of -$60664.0.
- Across the five-year window, Net Income towards Common Stockholders surged 137.93% in 2022 and tumbled 232.84% in 2023, its largest moves.
- Nu-Med Plus' Net Income towards Common Stockholders stood at -$112341.0 in 2021, then soared by 137.93% to $42606.0 in 2022, then sank by 232.84% to -$56596.0 in 2023, then soared by 81.35% to -$10555.0 in 2024, then fell by 19.55% to -$12618.0 in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$12618.0 (Q4 2025), -$11966.0 (Q3 2025), and -$11665.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Nu-Med Plus | - | - | - | -12,618.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,618.00 |
| Sep 30, 2025 | -11,966.00 |
| Jun 30, 2025 | -11,665.00 |
| Mar 31, 2025 | -19,933.00 |
| Dec 31, 2024 | -10,555.00 |
| Sep 30, 2024 | -18,677.00 |
| Jun 30, 2024 | -17,287.00 |
| Mar 31, 2024 | -21,826.00 |
| Dec 31, 2023 | -56,596.00 |
| Sep 30, 2023 | -16,406.00 |
| Jun 30, 2023 | -24,320.00 |
| Mar 31, 2023 | -28,204.00 |
| Dec 31, 2022 | 42,606.00 |
| Sep 30, 2022 | -58,050.00 |
| Jun 30, 2022 | -58,070.00 |
| Mar 31, 2022 | -59,653.00 |
| Dec 31, 2021 | -112,341.00 |
| Sep 30, 2021 | -118,366.00 |
| Jun 30, 2021 | -242,606.00 |
| Mar 31, 2021 | -356,748.00 |